Search

AbCellera Biologics Inc

Открыт

СекторЗдравоохранение

11.67 2.55

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

10.89

Макс.

11.66

Ключевые показатели

By Trading Economics

Доход

-55M

-99M

Продажи

-4.3M

4.1M

Прибыль на акцию

-0.18

Рентабельность продаж

-2,434.37

Сотрудники

562

EBITDA

-645K

-42M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+50.45% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.8B

3.6B

Предыдущая цена открытия

9.12

Предыдущая цена закрытия

11.67

Новостные настроения

By Acuity

41%

59%

99 / 339 Рейтинг в Healthcare

AbCellera Biologics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 сент. 2026 г., 23:06 UTC

Correlated Moves

Abcellera Biologics shares declined in after-market trading, reflecting broader market concerns after a drop in the New York Empire State Manufacturing Index.

14 сент. 2026 г., 20:08 UTC

Correlated Moves

Abcellera Biologics is advancing as positive sentiment from Schrödinger's licensing agreement with Tectora Therapeutics influences market activity.

11 сент. 2026 г., 23:06 UTC

Abcellera Biologics Inc. shares declined in after-market trading, with no specific company news identified. Broader inflation concerns may be influencing market sentiment.

10 сент. 2026 г., 20:07 UTC

Abcellera Biologics Inc shares are lower today, continuing a decline since Wednesday's close. The stock trades significantly below its 20-day moving average.

4 сент. 2026 г., 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market selling pressure following a strong jobs report, despite earlier gains during the session.

3 сент. 2026 г., 23:05 UTC

Abcellera Biologics Inc shares are higher in after-market trading, supported by broader market gains amid easing interest rate hike concerns. No specific company news was identified.

1 сент. 2026 г., 20:08 UTC

Abcellera Biologics Inc shares are lower today amid broader market declines and rising oil prices, which have renewed inflation concerns and interest rate hike expectations.

31 авг. 2026 г., 23:06 UTC

Abcellera Biologics Inc shares declined in after-market hours, reflecting broader market sentiment influenced by comments on inflation and potential interest rate hikes.

28 авг. 2026 г., 23:01 UTC

Abcellera Biologics Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

26 авг. 2026 г., 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

25 авг. 2026 г., 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

24 авг. 2026 г., 23:36 UTC

Social Media

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

21 авг. 2026 г., 19:36 UTC

Social Media
Correlated Moves

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

20 авг. 2026 г., 19:16 UTC

Social Media
Correlated Moves

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

19 авг. 2026 г., 23:02 UTC

Social Media

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

18 авг. 2026 г., 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

17 авг. 2026 г., 23:06 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

14 авг. 2026 г., 19:44 UTC

Social Media
News

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

13 авг. 2026 г., 19:31 UTC

Social Media
News

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

12 авг. 2026 г., 20:02 UTC

Social Media
News

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

11 авг. 2026 г., 22:51 UTC

News

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

10 авг. 2026 г., 23:06 UTC

Correlated Moves
Event
News
Social Media

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

8 авг. 2026 г., 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7 авг. 2026 г., 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6 авг. 2026 г., 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 авг. 2026 г., 23:02 UTC

Social Media
News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 авг. 2026 г., 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 июл. 2026 г., 19:33 UTC

Correlated Moves
Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 июл. 2026 г., 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 июл. 2026 г., 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

Сравнение c конкурентами

Изменение цены

AbCellera Biologics Inc Прогноз

Целевая цена

By TipRanks

50.45% рост

Прогноз на 12 месяцев

Средняя 17.167 USD  50.45%

Максимум 30 USD

Минимум 9 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для AbCellera Biologics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

7

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

99 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat